This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Emami, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Emami, A.
Related Collections
Right arrow Hematology-Oncology

AAP Grand Rounds 3:62-63 (2000)
© 2000 American Academy of Pediatrics

HEMATOLOGY-ONCOLOGY

Maternal Anticonvulsant Therapy and Neonatal Blood Coagulation

Source: Hey E. Effect of maternal anticonvulsant treatment on neonatal blood coagulation. Arch Dis Child. 1999;81:F208–210.

The first 20% of the full text of this article appears below.

This prospective and longitudinal study was designed to investigate the impact of maternal anticonvulsant use on the blood coagulation of the newborn. The study was prompted by a report in 1970 describing the high incidence of prothrombin deficiency among infants born to mothers taking anticonvulsant treatment.1 During the 15 years of this study at Newcastle upon Tyne, cord blood prothrombin times were measured in 137 consecutive term newborns of mothers who were on chronic treatment with phenobarbitone, phenytoin, and/or carbamazepine. The anticonvulsant levels were measured in 131 mothers at delivery. A second umbilical venous sample was obtained in 83 of the newborns after administration of 1mg of intravenous vitamin K. . . . [Full Text of this Article]

Abbas Emami, MD
Hematology/Oncology,Children’s Mercy Hospital, Kansas City, MO